Blood-based analysis of circulating tumor DNA
The term liquid biopsy in the context of malignant diseases refers to various methodologies for the purpose of blood-based monitoring and genotyping of solid tumors with the advantage of being largely non-invasive as compared to tumor biopsies. Besides various assays for the determination and characterization of circulating tumor cells blood plasma-based assays for the genotyping of circulating cell-free DNA (cfDNA) and cfRNA of solid tumors have been entering the clinic. Key application of these assays are initial diagnosis, monitoring of response to treatment, and detection of minimal residual disease. Cutting-edge molecular technologies like Next-generation sequencing are the fundamental cornerstones of these innovative assays. The assays can detect genetic mutations in cancer-driving hotspot genes, tumor suppressor genes, gene copy number variations, as well as gene fusions. These genetic alterations are important molecular targets for personalized or precision medicine.
NextGen Oncology offers Oncomine™ Pan-Cancer cell-free assays. The Oncomine™ assay provides a comprehensive content for clinically relevant oncology molecule profiling.
Growing resistance is a frequent issue in the context of mutation-controlled therapies. The tumour resumes its growth. The reason for this is the emergence of new mutations that require an update of the treatment plan. By using the new class of molecular assays, the therapeutically relevant status quo of the tumour can be determined in real time at any point in time in order to adapt the treatment as early as possible.
Test sample requirements & Turnaround time
10 ml EDTA blood or 5 ml serum 
10 business days
Logistics
Our collection kit contains everything you need to collect and send blood samples by DHL Express.